SCHIZOPHRENIA AND HTA DECISION MAKING

被引：0
|
作者：
Chawla, T. [1 ]
Albero, Izquierdo R. [2 ]
Rube, M. [1 ]
Oshinowo, B. [3 ]
机构：
[1] CBPartners, New York, NY USA
[2] CBPartners, San Francisco, CA USA
[3] CBPartners, London, England
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMH36
引用
收藏
页码：S590 / S590
页数：1
相关论文
共 50 条
  • [41] HTA decision-making for drugs for rare diseases: comparison of processes across countries
    Tania Stafinski
    Judith Glennie
    Andrea Young
    Devidas Menon
    Orphanet Journal of Rare Diseases, 17
  • [42] COMPARATOR PRICING CONFIDENTIALITY AND TRANSPARENCY IN HTA DECISION MAKING: A COMPARATIVE ANALYSIS OF THE NORDIC MARKETS
    Lindblom, J.
    Mogard, O.
    Hultberg, M.
    VALUE IN HEALTH, 2022, 25 (01) : S106 - S106
  • [43] BEST PRACTICES FOR ECA STUDY DESIGN TO SUPPORT HTA DECISION-MAKING IN EUROPE
    Dumuolin, O.
    Vidalis, A.
    Proenca, C.
    VALUE IN HEALTH, 2022, 25 (12) : S339 - S340
  • [44] CAN EARLY US ADOPTION OF CANCER DRUGS INFORM HTA DECISION-MAKING?
    Jonsson, P.
    Mpofu, P.
    Kent, S.
    Copeland, A.
    Groves, B.
    Bargo, D.
    Ramsey, S.
    Baxi, S.
    Adamson, B.
    VALUE IN HEALTH, 2021, 24 : S51 - S51
  • [45] Categorisation of HTA agencies and their decision-making systems from regulatory approval to reimbursement
    Salek, S.
    Allen, N.
    Pichler, F.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 400 - 400
  • [46] CHARTING THE PROGRESS OF HTA IN ASIA: ARE WE READY FOR EVIDENCE BASED DECISION-MAKING?
    Kumar, R.
    Suharlim, C.
    Amaris, Caruso A.
    Gilmartin, C.
    Mehra, M.
    Castro, H.
    VALUE IN HEALTH, 2021, 24 : S186 - S186
  • [47] HTA for Medical Devices: Multiple-Criteria Decision Making as an Outcome Evaluation Tool
    Rosina, J.
    Rogalewicz, V.
    Ivlev, I.
    Jurickova, I.
    Donin, G.
    Vacek, J.
    Otawova, R.
    Kneppo, P.
    WORLD CONGRESS ON MEDICAL PHYSICS AND BIOMEDICAL ENGINEERING, 2015, VOLS 1 AND 2, 2015, 51 : 1367 - 1370
  • [48] CHARACTERIZING EVIDENTIARY CRITIQUES IN HTA DECISION-MAKING FOR TREATMENTS INDICATED FOR OVERWEIGHT AND OBESITY
    O'Brien, M.
    Siamopoulou, E.
    Oshinbolu, S.
    Budhia, S.
    VALUE IN HEALTH, 2024, 27 (12) : S363 - S363
  • [49] DECISION-MAKING IN NICE, SMC, AND NCPE: ASSESSING TIME FROM REGULATORY APPROVAL TO HTA DECISION OUTCOME
    Gribbon, E.
    Mcloughlin, D.
    Dooley, B.
    VALUE IN HEALTH, 2024, 27 (12)
  • [50] Interchangeability and substitution of biosimilars: is health technology assessment (HTA) a tool for decision-making?
    Ascef, Bruna de Oliveira
    Leonel da Silva, Renan Goncalves
    de Oliveira Junior, Haliton Alves
    De Soarez, Patricia Coelho
    CADERNOS DE SAUDE PUBLICA, 2019, 35 (09):
12345